S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:PMD

Psychemedics Stock Forecast, Price & News

$7.25
+0.07 (+0.97 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.05
Now: $7.25
$7.45
50-Day Range
$4.95
MA: $6.76
$7.70
52-Week Range
$3.58
Now: $7.25
$8.36
Volume16,464 shs
Average Volume50,525 shs
Market Capitalization$40.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.

Headlines

Psychemedics Corporation (PMD)
December 19, 2020 |  finance.yahoo.com
Where Do Hedge Funds Stand On Psychemedics Corp. (PMD)?
November 29, 2020 |  finance.yahoo.com
Psychemedics Announces Third Quarter Results
November 9, 2020 |  finance.yahoo.com
Psychemedics Announces Second Quarter Results
August 12, 2020 |  finance.yahoo.com
Hedge Funds Are Selling Psychemedics Corp. (PMD)
May 28, 2020 |  finance.yahoo.com
Psychemedics Announces First Quarter Results
May 13, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PMD
CUSIPN/A
Phone978-206-8220
Employees204
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.68 million
Cash Flow$1.37 per share
Book Value$3.05 per share

Profitability

Net Income$1.54 million

Miscellaneous

Market Cap$40.07 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Medical Sector

1079th out of 1,972 stocks

Medical Laboratories Industry

21st out of 39 stocks

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$7.25
+0.07 (+0.97 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What stocks does MarketBeat like better than Psychemedics?

Wall Street analysts have given Psychemedics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Psychemedics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Psychemedics?

Psychemedics saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 17,800 shares, an increase of 45.9% from the January 28th total of 12,200 shares. Based on an average trading volume of 56,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the company's stock are short sold.
View Psychemedics' Short Interest
.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Psychemedics
.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) issued its quarterly earnings results on Tuesday, April, 23rd. The company reported $0.11 earnings per share (EPS) for the quarter. The company had revenue of $9.82 million for the quarter. Psychemedics had a negative net margin of 15.55% and a negative trailing twelve-month return on equity of 19.93%.
View Psychemedics' earnings history
.

How has Psychemedics' stock been impacted by Coronavirus (COVID-19)?

Psychemedics' stock was trading at $6.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PMD stock has increased by 4.3% and is now trading at $7.25.
View which stocks have been most impacted by COVID-19
.

Who are Psychemedics' key executives?

Psychemedics' management team includes the following people:
  • Mr. Raymond C. Kubacki, Chairman, CEO & Pres (Age 76, Pay $556.2k)
  • Mr. Charles M. Doucot IV, Exec. VP (Age 55, Pay $346.2k)
  • Dr. Michael I. Schaffer Ph.D., VP of Laboratory Operations (Age 76, Pay $319.7k)
  • Dr. Werner A. Baumgartner Ph.D., Founder
  • Ms. Annette Baumgartner, Founder
  • Mr. Andrew Limbek, VP & Controller
  • Ms. Sarah Ashby, VP & Gen. Counsel
  • Mr. Patrick J. Kinney Jr., Sec.

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics CEO Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among Psychemedics' employees.

Who are some of Psychemedics' key competitors?

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different retail and institutional investors. Top institutional investors include Tieton Capital Management LLC (2.98%), Invenomic Capital Management LP (2.42%), Dimensional Fund Advisors LP (2.09%), Ancora Advisors LLC (1.55%), Blair William & Co. IL (0.44%) and Northern Trust Corp (0.43%). Company insiders that own Psychemedics stock include Charles M Doucot, Fred J Weinert, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr.
View institutional ownership trends for Psychemedics
.

Which major investors are selling Psychemedics stock?

PMD stock was sold by a variety of institutional investors in the last quarter, including Lapides Asset Management LLC, Dimensional Fund Advisors LP, LPL Financial LLC, Northern Trust Corp, Blair William & Co. IL, Tieton Capital Management LLC, and Ancora Advisors LLC.
View insider buying and selling activity for Psychemedics
or view top insider-selling stocks.

Which major investors are buying Psychemedics stock?

PMD stock was bought by a variety of institutional investors in the last quarter, including Invenomic Capital Management LP, and Santa Monica Partners LP. Company insiders that have bought Psychemedics stock in the last two years include Charles M Doucot, Fred J Weinert, Michael I Schaffer, and Raymond C Kubacki Jr.
View insider buying and selling activity for Psychemedics
or or view top insider-buying stocks.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $7.25.

How much money does Psychemedics make?

Psychemedics has a market capitalization of $40.07 million and generates $37.68 million in revenue each year.

How many employees does Psychemedics have?

Psychemedics employs 204 workers across the globe.

What is Psychemedics' official website?

The official website for Psychemedics is www.psychemedics.com.

Where are Psychemedics' headquarters?

Psychemedics is headquartered at 289 GREAT ROAD Suite 200, ACTON MA, 01720.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.